Matrix metalloproteinase

Matrix metalloproteinase. These are a large family of zinc-dependent endopeptidase enzymes that are crucial for the degradation and remodeling of the extracellular matrix. First identified in the 1960s during studies of tadpole tail resorption, their activity is essential for numerous physiological processes, from embryogenesis to wound healing. Dysregulated expression and activity are strongly implicated in the pathogenesis of many serious diseases, including arthritis, cancer metastasis, and atherosclerosis.

Structure and classification

The basic structural architecture includes a conserved catalytic domain containing a zinc ion coordinated by three histidine residues, which is essential for proteolytic activity. Most are synthesized as inactive zymogens, containing an inhibitory propeptide domain that maintains latency. They are systematically classified into several groups based on substrate specificity and domain organization, such as collagenases, gelatinases, stromelysins, and membrane-type MMPs. This classification system was formally established by researchers at the National Institutes of Health and is maintained by the International Union of Biochemistry and Molecular Biology. Key structural features, like the fibronectin type II inserts in gelatinases, were elucidated through X-ray crystallography studies at institutions like the MRC Laboratory of Molecular Biology.

Function and mechanism

Their primary function is the proteolytic cleavage of components of the extracellular matrix, such as collagen, elastin, and proteoglycans. This action is not merely destructive but facilitates critical tissue remodeling events. The enzymatic mechanism involves the activation of a water molecule by the zinc ion in the active site, enabling nucleophilic attack on the peptide bond of the substrate. Beyond matrix degradation, they process a wide array of non-matrix substrates, including cytokines, growth factors, and cell surface receptors, thereby regulating bioavailability and signal transduction. This broad substrate profile was a key discovery from laboratories at Stanford University and the University of California, San Francisco.

Role in physiology and disease

In normal physiology, they are indispensable for processes like angiogenesis, bone development, and uterine involution. Their tightly controlled activity is vital for proper morphogenesis and organogenesis. However, their dysregulation is a hallmark of many pathological conditions. In rheumatoid arthritis, excessive degradation of articular cartilage occurs, while in periodontitis, they destroy the periodontal ligament. Their role in facilitating tumor invasion and metastasis by degrading the basement membrane is a major focus of oncology research, with seminal work published in journals like *Nature* and *Cell*. Elevated levels are also documented in abdominal aortic aneurysm and multiple sclerosis.

Regulation of activity

Activity is controlled at multiple levels, including transcriptional regulation, zymogen activation, and inhibition by endogenous inhibitors. Key transcriptional regulators include AP-1 and Ets family proteins, often induced by signals from cytokines like interleukin-1 and growth factors such as platelet-derived growth factor. Activation of the latent proenzyme typically involves disruption of the cysteine switch mechanism by other proteases like plasmin or even by active MMPs themselves. The most critical endogenous inhibitors are the tissue inhibitor of metalloproteinases, a family of proteins whose discovery was concurrent with that of the enzymes at the University of Alabama at Birmingham.

Clinical significance and inhibitors

Given their central role in disease, they are prominent therapeutic targets. Broad-spectrum synthetic inhibitors, often hydroxamate-based compounds that chelate the catalytic zinc ion, were developed by companies like British Biotech but faced challenges in clinical trials due to side effects like musculoskeletal syndrome. More recent strategies focus on developing selective inhibitors or antibodies against specific members, such as those overexpressed in glioblastoma. Monitoring their levels or activity in serum or synovial fluid serves as a biomarker for disease progression in conditions like osteoarthritis and congestive heart failure, with assays developed following research at the Cleveland Clinic and Mayo Clinic. Category:Enzymes Category:Proteases